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INTRODUCTION
Clinical/translational research can be separated into
two components, T1 and T2. T1 research applies discov-
eries generated during preclinical laboratory research to
the development of clinical efficacy trials in humans,
leading up to the submission of a New Drug Application
or an amended New Drug Application claiming new uses
of an approved medication. The second component of
translation research, T2, is aimed at developing and iden-
tifying actions, interventions, or practices that enhance
the effectiveness of approved agents in the larger popu-
lation. The delivery of effective treatments through the
implementation and evaluation of best practice guidelines
within practice settings is another component of T2 re-
search, but some authors have broken this aspect of pa-
tient care and practice into a subcategory of T2 research or
simply labeled it as T3 research.1,2 Clinical and/or trans-
lational research are not new areas of research, but their
importance in improving the public’s health was height-
ened with the introduction of the National Institutes of
Health (NIH) Roadmap programs and by the Roadmap’s
Clinical and Translational Science Award (CTSA) pro-
gram which aims to consolidate a number of NIH clinical
research and training programs at the nation’s Academic
Health Centers (AHCs).3,4 A primary requirement for
a successful CTSA program is the demonstration of in-
volvement of several health professions colleges/schools
that are either members of the submitting institution’s
AHCs or from a medical school and health professions
programs at another institution. A number of the success-
ful CTSA applications have significant involvement of
colleges/schools of pharmacy.
In 2006-07, AACP President Marilyn Speedie
appointed an Educating Clinical Scientists Task Force
(ECSTF I) with a charge to explore how academic phar-
macy can increase its capacity for training clinical scien-
tists to expand pharmacy’s involvement in clinical and
translational research, particularly through the CTSA pro-
gram. The ECSTF I focused its efforts primarily on how to
best educate and train clinical/translational scientists to
contribute effectively in the area of bench to bedside re-
search (T1). The ECSTF I came to a consensus on a unique
education and training model for a Pharmacist Clinical
Scientist at the PhD level. This initial ECSTF presented
their recommendation to the 2007 AACP House of Del-
egates (HOD) in the form of a Policy Statement which was
approved by the HOD. The policy statement is as follows:
AACP encourages research intensive university phar-
macy programs associated with academic health cen-
ters (AHCs) to accept as a necessary component of
their research/graduate training mission, a significant
interdisciplinary education/training program for clin-
ical scientists in experimental pharmacotherapeutics
at the PhD level.
The proposed interdisciplinary PhD program in ex-
perimental pharmacotherapy is discussed in detail in the
ECSTF I report.5
Shortly after the release of the ECFTF I report, mem-
bers of the Academy started to inquire about the role of
pharmacy faculty in T2 education and research. There-
fore, 2007-08 AACP President Cynthia Raehl appointed
a second Educating Clinical Scientists Task Force
(ECSTF II) to continue the exploration of how academic
pharmacy can increase its capacity for education and
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research with a particular focus on T2 research from bed-
side to patient care.
ECSTF II met November 8-9, 2007 in Chicago, IL to
discuss the following charges from President Raehl:
1. Define all the potential research activities or
disciplines in colleges/schools of pharmacy that
deal with therapeutic agents that have received
FDA approval for use in patients. Confine your
considerations to T2 research as opposed to T1
research, the focus of ECSTF I.
2. After defining those areas of research that could
be the focus of colleges/schools of pharmacy
faculty, either as individual investigators or
members of a larger multi-disciplinary team of
researchers, assess the current state of the re-
search capability in the Academy.
3. Make recommendations to the Academy as to
the potential future of this type of research (T2)
within colleges/schools of pharmacy, recruit-
ment of faculty needed to accomplish the re-
search missions, and recommendations for
educating the next generation of these faculty
scientists in colleges/schools of pharmacy, from
current PharmD students to current pharmacy
faculty.
4. Identify opportunities for pharmacy college/
school faculty and students to engage in NIH
Clinical and Translational Sciences Awards
(CTSA) programs.
5. Identify existing Pharmacy Practice Based Re-
search Networks within the Academy.
BACKGROUND
Translational Research
The components of clinical and/or translational re-
search were discussed in detail in the ECSTF I report.5
Figure 1, adapted from Westfall, Mold, and Fagnan, illus-
trates the relationship of T1 to T2 research by expanding
and modifying terminology into recognizable pharmaceu-
tical science and pharmacy practice research focus areas.1
There has been increasing recognition of the impor-
tance of BEDSIDE TO PRACTICE or BEDSIDE TO
PATIENT(s) Clinical or Translational Research (T2).
This is a large part due to the Institute of Medicine reports
on adverse medical events, several high profile medica-
tion recalls due to unrecognized or unreported untoward
effects during Phase III clinical studies, and the Rand
studies which demonstrate that patients do not often re-
ceive appropriate medical care, primarily drug therapy,
for correctly diagnosed illnesses.6-12
T2 research attempts to define and understand all the
parameters for the effective use of an approved drug prod-
uct in the entire population of patients that are candidates
for that drug product or an alternative drug therapy. Most
importantly T2 research explores health practitioner and
patient behaviors that can lead to an increase in drug
effectiveness, reduce adverse drug events, or alternatively,
decrease or eliminate the need for drug therapy. These
Figure 1. The components of translational research as applied to the pharmaceutical sciences.
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goals of T2 research are not unfamiliar or unimportant to
academic pharmacy and pharmacy practice and are con-
sistent with the concept of pharmaceutical care. Examples
of T2 research include comparative drug effectiveness
trials, quality of life evaluations, drug-drug interactions,
and refinement of dosage regimens based on genetics,
organ function, age, and gender. Other examples include
patient, prescriber, and pharmacist behaviors that might
influence the choice of therapy (e.g., guidelines) or pa-
tient medication use (e.g., patient literacy, clinician-pa-
tient communication skills, self-management skills,
cultural factors), and non-medical factors such as insur-
ance payment policies (private or public) and the medical/
pharmacy practice environment. T2 research encom-
passes all those factors that lead to an enhanced or dimin-
ished effectiveness in treating disease in the broader patient
population after an intervention such as drug therapy has
been shown to be efficacious in a selected study sample.
The Current Involvement of Academic Pharmacy
in T2 Research
Examination of college/school of pharmacy websites
reveals that a significant number of colleges/schools of
pharmacy either offer advanced coursework and/or are
engaged in T2 research. Graduate programs in the Social
and Administrative Sciences (SAS) and/or Pharmacy
Practice list the following research focus areas which lead
to a graduate degree (M.S. or Ph.D.). The term Social and
Administrative Sciences is not used by all colleges/
schools of pharmacy, but the AACP Section containing
the majority of faculty in this field is termed Social and
Administrative Sciences and therefore is used throughout
this paper.
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Pharmacoeconomics and Outcomes Research (P/OR)
are probably the most commonly mentioned focus areas
for SAS graduate programs. In a follow-up survey of
graduate programs in P/OR completed in 1998-99, Jack-
son and Draugalis found that a extensive growth had taken
place in both the number of colleges/schools offering
graduate programs in these areas over a five year period,
along with a growth in the students enrolled in these pro-
gram areas.13 Of 41 colleges/schools offering graduate
degrees (MS and PhD) in SAS, 35 responded that P/OR
were part of their degree options. Examination of the
responding institutions websites confirms that these dis-
ciplinary areas remain a focus of many SAS graduate
programs. Jackson and Draugalis used the definitions of
P/OR from the International Society for Pharmacoeco-
nomics and Outcomes Research (ISPOR) lexicon.
Pharmacoeconomics has been defined as ‘‘the field
of study that evaluates the behavior of individuals,
firms, and markets relevant to the use of pharma-
ceutical products, services and programs, and
which frequently focuses on the costs (inputs) and
consequences (outcomes) of that use.
Outcomes research has been defined as ‘‘the col-
lection and analysis of data on the use of health care
products, procedures, services, and programs, and
the evaluation of clinical, economic, quality of life,
and patient satisfaction outcomes of that care, to
determine the value of the products, procedures,
services, and programs.
The behaviors of patients and providers can signifi-
cantly influence whether the goals of therapy, including
drug therapy are realized. According to the NIH Office of
Behavioral and Social Science Research (OBSSR), ‘‘the
core areas of behavioral and social sciences research are
those that have a major and explicit focus on the under-
standing of behavioral or social processes, or on the use
of these processes to predict or influence health outcomes
or health risk factors.’’14 Areas considered ‘‘behavioral’’
by OBSSR include cognition, emotion, temperament,
and motivation while the social sciences include socio-
cultural, -economic, and -demographic status.
Lonie et al. examined published abstracts from 1989-
1999 of SAS faculty members to determine the extent
of behavioral science research by SAS faculty.15 The
authors excluded research papers in a number of areas,
including those dealing with pharmacoeconomics, man-
agement and pharmaceutical care outcomes. The authors
found that the majority of selected behavioral science
publications explored topics such as attitudes, beliefs,
and perceptions of patients and pharmacists. Medication
issues/problems in the elderly were also a major topic.
Approximately half the publications focused on pharma-
cists’ feelings, beliefs, and attitudes toward the profession
and potential expanded roles in counseling, job satisfac-
tion, burnout, etc. Most studies were descriptive in nature
and few explored the impact of pharmaceutical care inter-
ventions on patients, particularly the elderly. There
was little or no attempt in any of the selected studies to
examine the effect of an intervention on health outcomes
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or health risk factors. In recent years, a small number
of SAS faculty have received NIH and the Agency for
Healthcare Research and Quality (AHRQ) research awards
for examining the efficacy of various interventions, in-
cluding pharmacists’ interventions, on the outcomes of
drug therapy.
Pharmacoepidemiology is a T2 research area often
used to detect adverse reactions, determine adherence to
prescribed regimens, and provide evidence as to the ef-
fectiveness of alternative therapies. Nwokeji et al. sur-
veyed pharmacoepidemiology education in US colleges/
schools of pharmacy, given that ACPE has included phar-
macoepidemiology as a required component of the phar-
macy professional degree curriculum.16 For the purposes
of the study, pharmacoepidemiology was defined as the
‘‘application of epidemiologic reasoning, methods, and
knowledge to the study of the uses and effects (beneficial
and adverse) of drugs in human populations.’’16 Research
in this area requires access to large medical databases
containing drug prescribing behavior such as those avail-
able in some private Health Maintenance Organizations
(HMOs) and government agencies such as the Veterans
Administration (VA) or Medicaid. Of the 89 (100%) col-
leges/schools responding to the survey, 83 percent indi-
cated they offered some level of pharmacoepidemiology
instruction, and 35 schools indicated they provided phar-
macoepidemiology to their MS or PhD students. Exami-
nation of 38 college/school websites for graduate
programs in SAS or Pharmacy Practice revealed several
programs listing pharmacoepidemiology as a focus area
for faculty research.
While informatics is not exclusively a T2 research
area, the use of digital information in electronic pre-
scriptions, patient records, and drug use patterns comple-
ments pharmacoepidemiology research. The AACP
Technology in Pharmacy Education and Learning (TiPEL)
Special Interest Group (SIG) published an article on
‘‘Implementing Pharmacy Informatics in College Curric-
ula,’’ informatics within pharmacy being defined as
using digital information to improve pharmaceutical out-
comes and student learning.17 Data management, infor-
mation acquisition and communication, research of both
patient and population-specific outcomes overlap with the
area of pharmacoepidemiology. The TiPEL SIG suggests
that academic pharmacy strongly consider developing
residency programs and graduate degree programs in in-
formatics to insure that pharmacy does not abdicate its
role to other health researchers in the emerging area of
informatics. Presently, there appears to be one informat-
ics graduate program that addresses clinical and transla-
tional research affiliated with a college/school of
pharmacy.
Pharmacy Practice departments without SAS faculty
members generally do not offer graduate degrees beyond
the MS level, but there is considerable interest in educa-
tion/training and research activity from faculty in this
discipline that is classified as T2. Pharmacy Practice fac-
ulty engaged in research focused on methods to optimize
or individualize therapy based on patient organ function
or genetics are involved in T2 research, as are those ex-
ploring the impact of various pharmacist interventions in
modifying drug therapy. The American College of Clin-
ical Pharmacy’s (ACCP) research agenda identified six
high-priority research areas, all of which can be charac-
terized as T2 research.18 These are:
1. Identify and evaluate patient, clinician, and sys-
tem factors that contribute to the safe and effec-
tive use of drugs in clinical practice.
2. Evaluate the effects of drugs on patient clinical,
humanistic, and economic outcomes in settings
typical of routine clinical practice.
3. Develop and use data repositories and novel
population-based methods to identify new indi-
cations or uses of drugs, and for identification
and confirmation of new adverse events.
4. Characterize general patterns of drug use, and
their use in populations not previously studied,
to determine their effect on clinical, humanistic,
and economic outcomes.
5. Identify and evaluate patient, clinician, and
system factors that influence the provision and
effectiveness of care provided by clinical phar-
macists.
6. Evaluate the effect of pharmaceutical care de-
livery models and other pharmacy services on
patient clinical, humanistic, and economic out-
comes.
ACCP has also supported further education in P/OR
by developing guidelines for fellowships in these areas of
research. The organization and outcomes of these ACCP
fellowships were evaluated and judged to be appropriate
models to develop expertise in the areas of P/OR needed,
particularly in the pharmaceutical industry.19-21
Thus, both SAS and Pharmacy Practice faculty at
colleges/schools of pharmacy provide instruction or con-
duct research in areas relevant to T2 research, although
some may not be aware that it is categorized under that
rubric. The cited studies of pharmacy faculty involvement
in research and graduate education in P/OR and social
and behavioral research are somewhat dated,13,15 but
the study results are consistent with the focus areas listed
on contemporary pharmacy college/school websites de-
scribing graduate degree program focus areas. Practice-
based research networks (PBRNs) that specifically utilize
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an organized group of practice environments for T2 re-
search is just starting to be undertaken in pharmacy.
The Impact of Social and Administrative Sciences
and Pharmacy Practice on T2 Research
There have been and are now, a small cadre of SAS
and Pharmacy Practice faculty who are recognized by
their peers both inside and outside of academic pharmacy
as excellent T2 researchers and contributors to the discov-
ery, understanding, and evaluation of the multiple factors
that contribute to patient outcomes from drug therapy.
There is a second and somewhat larger group of SAS
and Pharmacy Practice faculty known for their T2 re-
search, much of it descriptive, within academic pharmacy
and the local or regional practice community, but who are
unknown outside of academic pharmacy. The third and
largest group SAS and Pharmacy Practice faculty contrib-
ute little to the area of T2 research either because their
research interests lie elsewhere, they are interested but not
prepared to conduct T2 research, or they are not interested
in research.
The members of the first two groups of faculty pri-
marily differ in focus and funding of their research. Con-
ducting intervention research requires much more
funding than descriptive research. Funds are needed for
recruiting patients and/or practitioner collaborators, sal-
aries for personnel to conduct the intervention, and the
data analysis. Intervention research may involve graduate
students or fellows but cannot be carried out solely by
these trainees. Federal agencies are the primary sources
for the amount of money required for conducting inter-
vention research. Pharmacy faculty members must con-
vince study sections comprised of scientists from multiple
disciples that they have the expertise and ability to carry
out the proposed interventional research study. Assuming
the proposed research is addressing a significant health
problem, the funding of the proposal will be graded on
whether the investigator has the recognized expertise,
both educational and experiential to carry it to successful
completion. To obtain the requisite expertise, an investi-
gator must focus on a research area that has significance to
the public’s health, not the profession of pharmacy.
Successfully funded research can and does involve
pharmacy and pharmacists, but utilizes pharmacy/phar-
macists as a treatment or intervention in an outcomes
study, not as the raison d’être of the study. Successfully
funded investigators are connected and can enlist col-
leagues as co-investigators or consultants from across
their campus and others to significantly improve chances
for funding their research proposal and ensure a successful
outcome to the research project. Interestingly, many but
not all SAS funded faculty received their graduate educa-
tion outside of SAS in one of the disciplines that forms the
knowledge base for SAS.
The second group of SAS and Pharmacy Practice
faculty are often academically prepared in SAS graduate
programs or Pharmacy Practice fellowships, but a reluc-
tance to apply for or an inability to obtain significant
funding, specifically to conduct outcomes research, leads
them to jump from research area to research area, never
developing the requisite expertise needed to obtain sig-
nificant federal agency funding. In Pharmacy Practice,
projects, particularly those funded by the pharmaceutical
industry are necessarily designed so that they can fit into
the one or two year time frame or a residency or fellow-
ship. As a result, much of the research of this faculty group
is descriptive and focuses on aspects of pharmacy practice
or pharmacists. These SAS and Pharmacy Practice faculty
publish almost exclusively in pharmacy journals, and as
a result, their research findings are primarily confined to
pharmacy and their disciplinary peers. Their funding
comes almost exclusively from pharmacy associations/
foundations who are interested in obtaining data to prove
the ‘‘value’’ of pharmacy services or pharmacists, or from
the pharmaceutical industry which is looking for study
results to provide a marketing advantage for one of their
products. Some SAS and Pharmacy Practice faculty have
obtained state agency funding, often through contract re-
search designed to assist various state agencies improve
drug utilization in programs such as Medicaid, and thus
have developed expertise in T2 outcomes research.
Federal agencies which fund health-related research
are not interested in pharmacists’ perceptions/attitudes or
the economic well being of pharmacy or pharmacists, as
they view the medication use process as primarily con-
trolled by physicians or other prescribers, not pharmacies
or pharmacists. However, these agencies are interested in
whether pharmacy services or pharmacists’ interventions
can improve patient outcomes and improve public health.
While there are studies that document the value of phar-
macy services in managing various chronic diseases and
their medications, many of these studies lack control
groups (they are simply pre-, post-designs), include nu-
merous biases, do not control for critical potential con-
founding variables and do not have rigorous clinical trial
designs.22-24
The third and perhaps largest cohort of both SAS and
Pharmacy Practice faculty are not involved in T2 re-
search. In SAS, many faculty are engaged in research
other than T2 because of the breadth of topics that make
up this field. Sorofman defined SAS as ‘‘. . . not pharma-
ceutics, not medicinal chemistry, not pharmacology, and
not clinical sciences—but everything else that makes up
the practice of pharmacists, the system of pharmacy in
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society (including education), human behavior, social in-
teraction, and the consumption of drugs.’’25 Sorofman’s
definition of what SAS is not has been oft-quoted, and is
used to explain the wide variety of topics taught by SAS
faculty in the professional degree curriculum. However,
there is a statement from Sorofman’s same presentation
that deserves more attention than the ‘‘not’’ definition,
given at an AACP Conference on the Future of Graduate
Education in the Pharmaceutical Sciences. His charge
was to look to the future of graduate education and re-
search in SAS. In discussing the changes occurring in the
social/health care environment, science and science edu-
cation, Sorofman spoke of the need for more interdis-
ciplinary and multidisciplinary approaches in SAS
research. To quote:
The analyses of outcomes, whether they are
humanistic, economic, and even clinical, of phar-
macist practices and pharmacotherapy, and the es-
tablishment and evaluation of the structure and
function of a health care system including phar-
macy are within our domain. There is no question
of need for scientists in the Social and Administra-
tive Sciences.25
This would imply that the major focus of SAS in the
future is outcomes research broadly defined. While many
SAS faculty are involved in outcomes research and stud-
ies of the structure and function of the health care system
as it relates to patient safety—pharmacy education,
assessment of educational outcomes, professionalism,
marketing and sales, regulatory/legal affairs, and man-
agement sciences remain a significant part of SAS. How
SAS can increase its national profile in outcomes-related
research, and teach and conduct research in all the other
areas presently imbedded in SAS poses a challenge to the
field, academic pharmacy, pharmacy practice, and its role
in the larger health care system.
With few exceptions, SAS faculty of the 1970s were
not interested in assessing the outcomes of the developing
practice model of clinical pharmacy. Marketing and man-
agement was still a primary focus of SAS graduate pro-
grams throughout the 1970s and early 1980s. The discipline
that emerged to provide an evidence base to assist phar-
macy graduates succeed as small business owners was
slow to change its focus as the profession changed from
individual to corporate ownership and from its product to
patient orientation. The interdisciplinary and multidisci-
plinary (SAS and Pharmacy Practice) approach to re-
search called for by Sorofman was not and still is not
practiced in many colleges/schools of pharmacy today,
even when the two disciplines have been combined under
the same administrative umbrella, although that now
appears to be changing.
ACCP, the association recognized for supporting re-
search in clinical pharmacy issued a research agenda in
2006, ‘‘Ensuring Medication Effectiveness and Patient
Safety’’ which is congruent with the focus areas of T2
research.18 Pharmacy Practice faculty teach and interact
with patients at the bedside in acute care facilities, with
patients or caregivers in chronic care facilities, and in
a variety of ambulatory care clinical environments, inclu-
ding the community pharmacy. The goal of the
pharmacist in all these environments is to optimize or
individualize patient drug therapy to maximize desired
clinical outcomes including quality of life and minimize
toxicity or undesirable adverse events. Practicing phar-
macists, whether they have an academic appointment or
not, could be and should be conducting outcomes research
on each and every patient they encounter. However, many
Pharmacy Practice faculty do not view ‘‘practice’’ as an
environment for outcomes research, nor do they view
treating individual patient’s problems as scholarly activ-
ity. The result of this separation of practice and the prac-
tice site from research or scholarly activity within the
Academy has been that pharmacy lacks a large body of
rigorous data demonstrating the ‘‘value’’ of various phar-
macist interventions on patient outcomes of drug therapy,
particularly in ambulatory care. Certainly, pharmacists
and academic pharmacy have convinced themselves of
the pharmacist’s value, and the profession has made
inroads with some states, federal agencies, and private
insurers of the value of pharmacist medication manage-
ment, but pharmacy has not convinced the broader public
or organized medicine of the importance of the pharma-
cist’s role in patient care.
One reason a ‘‘gap’’ exists in the perceived value of
patient-oriented pharmacy practice amongst the public
and the funders of health care is that the Academy has
not done rigorous and appropriate research to demonstrate
the pharmacist’s value outside of the profession itself.
Why not? In the early 1970s, when clinical pharmacy
was emerging, the post-BS PharmD programs of that
era focused much of their effort in establishing practice
sites and on improving pharmacist-physician interaction,
often through the tools of biopharmaceutics and pharma-
cokinetics, not on pharmacist-patient interactions. The
value of pharmacists’ improving drug dosing utilizing
the tool of pharmacokinetics had impact on individual
patients, but the interventions were often with the pre-
scribing physicians, not the patient.26,27 There was little
pharmacist-patient outcomes research done on these
many studies because the new clinical faculty were not
educated and trained to evaluate their then new interven-
tions. The new Pharmacy Practice faculty members re-
quired the assistance and collaboration of colleagues who
American Journal of Pharmaceutical Education 2008; 72 (Supp) Article S10.
6
were interested in the new practice model and had the
expertise to evaluate the new and evolving clinical role
of pharmacists, but collaborations were infrequent.
A significant factor contributing to the paucity of T2
research by Pharmacy Practice faculty with a PharmD
degree is a lack of education, training, and experience to
carry out this type of research.28 Students in the PharmD
degree program receive limited exposure to research meth-
odology. ECPTF I recommended a change in the accredi-
tation guidelines to address this deficiency in the PharmD
program. This deficiency is not remedied by a residency, as
most residency programs have either dropped or dimin-
ished the research component in lieu of more patient care
responsibilities. Faculty with a PharmD degree and resi-
dency training could perform research, but most do not.
There are examples of SAS and Pharmacy Practice faculty,
including those in non-tenure track positions, who have
published important T2 research.29-47 Some of these stud-
ies have become some of the most highly cited in the med-
ical literature in recent years.30,34 This small cadre of
excellent T2 researchers in Pharmacy Practice are the ex-
ception, not the rule.48,49
The Future and Importance of Social and
Administrative Sciences in T2 Research
Given the importance of T2 research in improving
drug therapy outcomes, a primary mission of pharmacy
and pharmacy education, why have a significant number
of colleges/schools of pharmacy, particularly those with
active graduate programs in the pharmaceutical sciences,
chosen not to support graduate education and the neces-
sary accompanying T2 research programs in SAS? Com-
pared to the number of institutions that offer graduate
degrees in the pharmaceutical sciences, SAS has the least
number of PhD-granting programs, the smallest graduate
school enrollment and smallest number of PhD graduates
of any other pharmaceutical sciences discipline and the
smallest amount of research funding.50 During the 1990s,
the number of PhD degrees granted in either SAS and/or
Pharmacy Practice was relatively small, averaging ap-
proximately 30 per year.51 The number of PhD degrees
granted from 2000-2006 has averaged 45 per year, only
enough to replace those SAS positions presently vacant,
those opening up because of retirement and those needed
to staff new colleges/schools of pharmacy. That assumes
that most SAS PhD graduates would accept an academic
position. The majority will probably accept a non-
academic position or an academic position in a non-U.S.
college/school of pharmacy as approximately 50 percent
of recent SAS PhD graduates are foreign students, so
some will return to their home countries to faculty or
private sector positions.
The large percentage of foreign students comprising
graduate program enrollment in PhD programs in all the
pharmaceutical sciences is not a recent phenomenon, but
the increase in foreign student enrolment is more recent
and dramatic in SAS. In 1990, less than 20 percent of the
total enrollment in SAS PhD programs consisted of for-
eign students. Foreign students became a majority in
2002, and in 2006 was 54 percent of total fulltime PhD
enrollment, second only to that of pharmaceutics. The
absolute number of US pharmacy graduates enrolled full
time in PhD programs in SAS has remained relatively low
(approximately 75) but constant from 1990-2005.51 Thus
foreign students have provided most of the enrollment
growth in SAS PhD programs over the same time period.
Why are not more US PharmD graduates attracted to
SAS, the pharmaceutical sciences discipline whose main
goals are the study of all those factors which can influence
patient drug therapy outcomes? Certainly, the financial
incentives to enter practice upon graduation, coupled with
the increasing debt loads of the contemporary student and
the relatively low wages of a teaching or research assis-
tantship act as a potential deterrent to entering a graduate
program. However, financial considerations alone do not
deter thousands of pharmacy graduates each year from
entering into residency programs. Is there a perception
on the part of PharmD students that graduate programs
in SAS are not patient oriented but more focused on da-
tabase analyses, survey methodology, and policy analy-
ses, making them less attractive to the contemporary
professional student? Or alternatively, are the four or
more years required for a degree too unattractive in the
current environment with high pharmacist salaries?
Unique and critical areas of research which focus on
drug therapy outcomes broadly defined are not strongly
supported in academic pharmacy, through sufficient fac-
ulty numbers and graduate education programs at many of
our research intensive colleges/schools of pharmacy. In
turn, the lack of a strong research focus and impact in this
important area throughout the Academy contributes to
a lack of interest in graduate education by US PharmD
students. One obvious solution would be to hire more SAS
faculty with the hope that this would increase scholarly
productivity in the discipline. A common reason given for
why SAS has not been more productive in research is too
much teaching responsibility and lack of a ‘‘critical
mass’’ of faculty. With regards the size of the SAS faculty,
the numbers of full-time faculty in SAS who are not deans
is approximately 60 percent of the other pharmaceutical
sciences such as pharmaceutics, medicinal chemistry, and
pharmacology/toxicology.52 The counter argument to in-
creasing the size of the SAS faculty is that the discipline is
not effective in attracting research funding, particularly
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funding from federal agencies that also provide indirect
costs to the institution. External funding is necessary to
fund both research and graduate student stipends, as fewer
institutional funds are available for those purposes.
Therefore, unless the discipline can demonstrate the abil-
ity to obtain in more external funding, it will be difficult to
support new graduate programs.
The SAS faculty have a legitimate argument that the
discipline does not receive the same ‘‘support’’ from the
Academy as the other pharmaceutical sciences. For ex-
ample, start-up funds for a new SAS faculty pale in com-
parison to the other pharmaceutical sciences, where
equipment and lab support now reach a million dollars
and $250,000-$500,000 is not uncommon. However,
a return on investment of start up funds of this magnitude
is expected in the form of NIH research dollars. Would
larger start-up support of SAS faculty for research assis-
tants result in the same return on investment as is achieved
in other pharmaceutical science disciplines? Addition-
ally, financial support for other new pharmaceutical sci-
entists is usually predicated on building up a focus area of
the discipline or adding a new research area that is being
supported by federal funding. Available federal funding
for a research area is now considered in the hiring of new
SAS faculty, but given the fact that past funding has gen-
erally come from the pharmaceutical industry or state
agencies, this was not a common practice. Additionally,
other pharmaceutical sciences faculty are often hired after
demonstrating the ability to do scholarly work, particularly
through multiple years of postdoctoral training. Most
SAS faculty move directly from graduate school into an
academic position, and unless they have had the ability to
publish before completing their thesis, they may spend the
first several years in an academic position publishing their
thesis project. They often do not experience the chance to
practice writing a grant proposal, unless that is a require-
ment of the graduate degree program. Therefore, in addi-
tion to not receiving an equivalent start up package, the
new SAS faculty member does not have the research and
publishing experience that their colleagues in the other
pharmaceutical sciences have accrued through their post-
doctoral experience. Combine this with teaching assign-
ments across several years of the curriculum and it is not
surprising that scholarly activity gets off to a slow start.
With regards to research/scholarship, SAS faculty re-
search interests have considerable diversity. While this is
true in the other pharmaceutical sciences, increasingly
these other disciplines have recognized that focusing the
department or division in an area of research, with indi-
vidual faculty bringing in unique expertise and technical
skill is highly desirable, particularly for obtaining larger
program project grants and common equipment or form-
ing institutes or centers on the university campus with
other related disciplines. This does not suggest that every
SAS graduate program have a single or identical research
focus, but some area of T2 research should be a major
focus, particularly as it relates to drug therapy outcomes.
This is particularly important as research becomes more
multi- and interdisciplinary across the university. If drug
therapy outcomes, broadly defined, is not a major focus
of SAS research, and SAS departments/divisions are not
viewed as the experts in this most important area of public
health, other disciplines in the health sciences such as
public health, economics, and medicine will continue to
have highest profile in drug therapy outcomes research
and pharmacy will continue to have little impact and may
not be invited to become part of university or Academic
Health Center programs.
To improve pharmacy’s research excellence in the
area of T2 research and graduate education, actions will
be necessary to increase SAS’s integration into the T2
research community on campus. SAS departments/divi-
sions must view the research expertise sought in new
faculty hires from the larger needs of the university T2
research community, not from the immediate teaching
needs of the PharmD program. A new SAS faculty mem-
ber who brings research expertise to the university or
academic health center or public health community not
just the college/school of pharmacy, can result in joint
appointments and the contribution of other university
units to salary and start up costs. The impact of this type
of hire is increased research collaboration across univer-
sity units. AHRQ programs such as the Centers for
Education and Research in Therapeutics (CERTs) and
Developing Evidence to Inform Decisions about Effec-
tiveness (DEcIDE) Networks not only require collabora-
tion across the university, but often among different
university units and health care facilities.53,54 Involving
SAS faculty and graduate students in large collaborative
research projects is important if academic pharmacy
desires to increase its impact in health care research and
practice.55
With the transformation of the profession away from
the pharmaceutical product to the patient, the ultimate
goal of providing a body of knowledge to assist pharma-
cists be more effective and efficient in carrying out their
responsibilities to society remain paramount. SAS grad-
uate programs must change to address the new realities of
drug therapy and health care.
The Importance and Future of Pharmacy Practice
in T2 Research
Pharmacy Practice’s future research goals as identi-
fied by ACCP are all essentially T2 in focus and scope, but
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the problem facing most Pharmacy Practice faculty is not
what type of research to conduct, but how to conduct re-
search. The problems facing outcomes researchers are
qualitatively different from those conducting other types
of research, but the education and training required for
conducting this type of research are no less rigorous. Mas-
ters level education and training such as available through
the NIH’s K23 program will provide some Pharmacy
Practice faculty with a larger set of skills to conduct T2
research. For the current PharmD student, in addition to
increasing the exposure to research methodology in the
professional degree program, Masters degree programs
could be offered as part of a concurrent dual degree pro-
gram within the college/school of pharmacy in SAS or
alternatively in a school of public health or public policy if
T2 research expertise is not available within the SAS
faculty. A full or part-time Masters-level degree program
with or without a residency/fellowship following gradu-
ation could also provide needed research tools. However,
if the pharmacy Academy is going to be a major contrib-
utor in the area of T2 research on a national level, there
must be a larger number of PharmD graduates educated
and trained at the PhD level, either in a PhD program in
the SAS or the disciplines found in schools of public
health. That means that more PharmD students must be
attracted to PhD graduate programs in the SAS.
Given that over one-half of full-time pharmacy fac-
ulty are Pharmacy Practice faculty, the most expeditious
way to expanding T2 research in academic pharmacy is
through increasing the involvement of Pharmacy Practice
faculty in research. All full-time Pharmacy Practice fac-
ulty should contribute to scholarly T2 research, not just
those on tenure track. While many of these faculty will not
necessarily be independent researchers, all members of
the Academy should be collaborating on such research.
This is not simply a matter of adding more requirements
for promotion and/or tenure. The future of pharmacy
depends on expanding our knowledge base of what works
and what does not work in pharmacists’ attempts to im-
prove patient drug therapy outcomes. The approach must
be multi-pronged given the large number of pharmacy
practice faculty, the majority of whom are at the assistant
professor level with little or no research or research train-
ing experience.50 Some new Pharmacy Practice faculty
should be encouraged or required to apply for an NIH K23
award, while others can take advantage of courses offered
through an institution’s CTSA award.56 All Pharmacy
Practice faculty members should identify faculty either
within the college/school’s SAS faculty, the school of
public health, the college of medicine, or at their practice
site to develop a collaborative research program. As noted
below, the American Academy of Family Physicians has
been a leader in promoting practice-based research for
all Family Physicians, including non-academic practi-
tioners. We believe that all academic pharmacy faculty
should be held to similar expectations regarding T2 re-
search. For those Pharmacy Practice faculty who have the
academic preparation to conduct outcomes research, the
provision of adequate startup funding and reasonable
teaching responsibilities in the first several years of their
appointment is as important to them as to pharmaceutical
sciences faculty. Investment in bridging research support
for those Pharmacy Practice faculty who complete a K23,
K08, or CTSA-sponsored Master’s degree program
would also insure that the investment in faculty develop-
ment through these programs is not wasted.
Educating and Training the Next Generation
of Academic Pharmacy T2 Researchers
The source of graduate students for T2 research pro-
grams needs to be expanded. Practitioners of T2 re-
search should have an understanding of the drug therapy
and disease processes under investigation, and should be
aware of the standard tools used for measuring clinical
outcomes, or alternatively develop and validate new
tools. Studies must be theoretically grounded, rigorously
designed and methodologically sound. A pharmacy back-
ground would be highly advantageous to an individual
interested in conducting T2 research, but graduate pro-
grams in colleges/schools of pharmacy which focus on
developing T2 researchers should also actively recruit
other health professions graduates including physicians,
nurses, physician assistants, allied health professionals,
and students with backgrounds such as sociology, psy-
chology, and economics.
In hiring new SAS faculty, while the teaching require-
ment of the PharmD degree program cannot be ignored,
an individual with a strong background in T2 research and
having an interest in factors which can influence drug
therapy outcomes should be competent to address re-
quired professional degree competencies. Programs also
must look beyond graduates of SAS PhD graduate pro-
grams for their new faculty. While an argument can be
made that a contemporary professional degree pharmacy
graduate who obtains a SAS PhD offers a unique perspec-
tive on T2 research, there are few such graduates each
year. The other pharmaceutical sciences have always
strengthened their research programs by hiring scientists
educated outside of colleges/schools of pharmacy. Given
that SAS is such a broad field of study with many applied
areas of research, it is important that individuals who
are educated to conduct research in disciplines such as
social science, educational psychology, economics, pub-
lic health, and epidemiology are incorporated into SAS
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graduate faculties to bring new ideas and perspectives to
the problems facing health care and pharmacy practice.
The Role of Pharmacy Practice-based Research
Networks (PBRNs) in T2 Research
What about the large numbers of Pharmacy Practice
faculty who have been practicing in an institutional, am-
bulatory care, or community pharmacy setting for a num-
ber of years? How can academic pharmacy involve these
individuals in more research without disrupting their
practice sites or add to their heavy teaching loads? One
way is to recruit them into participating in the emerging
Pharmacy Practice-based Research Networks (PBRNs).
Pharmacy PBRNs are organized groups of practitioners
which meet a certain threshold in term of practice sites,
clinicians, mission, administration/management, com-
munity involvement, and communication.56 Initially started
by American Academy of Family Practice, PBRNs have
been recognized for their significant role in improving pa-
tient care through their conduct of research on practice in
practice.1,58 These physicians face the same pressures to see
patients, and sometime teach, as do non-tenure track Phar-
macy Practice faculty. Private physicians and non-tenure
track pharmacy faculty will usually not be expected to be
independent principal investigators on T2 research. How-
ever, their participation is critical to the success of T2 re-
search. All Pharmacy Practice faculty should be expected
to collaborate on T2 research and one outstanding oppor-
tunity is through PBRNs.
Practice-based research carried out through orga-
nized PBRNs can play an extremely important role in
filling the knowledge gap of what happens after a patient
receives a diagnosis and is given a prescription. What role
do pharmacy-patient, pharmacy environment, patient-
insurer, patient-disease, patient-literacy, etc., factors play
in the acute and long-term outcomes of patient care? Re-
search on practice factors conducted in practice settings
by pharmacists, whether they be full or part-time phar-
macy faculty, or practitioners serving as adjunct faculty
preceptors will give academic pharmacy an important
tool in understanding what practice works best when it
comes to obtaining optimal patient outcomes from drug
therapy. PBRN involvement is just not for Pharmacy
Practice faculty. PBRNs are an excellent venue to form
collaborations of SAS and Pharmacy Practice faculty with
the larger practice community.
There has been much research on pharmacy practice,
but not through organized PBRNs. However, the year
2007 was significant for Pharmacy PBRNs with an
AACP-sponsored conference, ‘‘Embracing the PBRN
Model to Improve the Medication Use Process,’’ and a pub-
lication describing the first primary care pharmacist
(PBRN)57,58 At the 2008 Annual Meeting of the American
Pharmacists Association (APhA), significant program-
ming was devoted to Pharmacy PBRNs, with a number
of papers presented at that conference published in the
journal of the Association.61-63 Pharmacy faculty have
served as Directors of PBRNs and one PBRN has been
formed in a national network of primary care clinics
throughout the U.S. also directed by a pharmacy faculty
member. These are outstanding opportunities for Phar-
macy Practice faculty to assist with T2 research. It is not
within the scope of this paper to review the PBRN model or
explain how these organizations provide opportunities for
collaboration between SAS and Pharmacy Practice faculty.
The AACP and APhA conferences provide sufficient ma-




1. Research that explores the social, economic, or-
ganizational, and clinical factors that influence
the outcomes of drug therapy of disease should
be a central mission of all colleges/schools of
pharmacy.
Note: The AACP 2008 House of Delegates
passed the following policy statement
recommended by the AACP Board of Directors:
Research that explores the social, economic,
organizational and clinical factors that influence
the outcomes of drug therapy in prevention or
treatment of disease should be central to the
mission of all colleges/schools of pharmacy.
2. Colleges/schools of pharmacy and their SAS
faculty should develop strategic partnerships and
alliances with Schools of Public Health to
enhance graduate program training and research
collaborations to enhance their capacity and
competitiveness.
3. Colleges/schools of pharmacy should foster strong
interdisciplinary research teams that include
Pharmacy Practice, SAS faculty and qualified and
complementary faculty investigators from
medicine, nursing, public health, and other
disciplines. The primary focus of these teams
should be to obtain federal funding to conduct
research in an area of expertise of the team and to
provide funding for graduate students.
4. SAS and Pharmacy Practice faculty should
develop the expertise in an area of T2 research
such that they can lead interdisciplinary research
teams and submit competitive applications for
federal funding.
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5. Pharmacy Practice PharmD full time faculty must
take advantage of NIH K08 or K23 Career
Development Awards (or VA Health Services
Research & Development (HSR&D) mentored
awards).
6. SAS Faculty at colleges/schools of pharmacy
with graduate programs should be expected to
pursue individual investigator awards either as
a PI or co-PI from AHRQ or the NIH.
7. Every college/school of pharmacy at an
institution that has, or is planning for a CTSA
must be integrated into the training and research
components of these awards.
8. Colleges/schools of pharmacy should identify
junior clinical faculty who can enter research
training programs (e.g. CTSA or K23) and
require them to apply for an award within the first
three years of their appointment. If possible, the
tenure clock, if it applies, should be suspended
during the award period.
9. Colleges/schools of pharmacy must increase
professional student competencies in T2 research.
ECSTFII reaffirms the recommendation of the
ECSTF I that all students must receive
appropriate training in T2 research and supports
a new ACPE standard in this regard.
10. All Pharmacy Practice faculty, including non-
tenure track, should be involved in T2 research
either as a co-investigator or participating
practitioner in a practice-based research network.
Note: The AACP 2008 House of Delegates
passed the following two policy
statements recommended by the AACP Board of
Directors:
AACP and colleges/schools of pharmacy
should promote pathways of faculty
development that enable pharmacy faculty
members, including non-tenure track faculty, to
lead and/or participate in practice-based
translational research.
AACP and colleges/schools of pharmacy should
promote pathways of faculty development and
the requisite infrastructure for research that
enable faculty members to lead or participate in
practice-based research networks.
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